Greggs has announced a “robust performance” for the first half of the year, with pre-tax profit up 7.3% to £16.5m. The bakery retail chain saw sales increase by 4.4% to £312m, with like-for-like growth up 1.5%. Operating profit stood at £16.3m – an increase of 8.9%, for the 26 weeks to 27 June, 2009.The firm said the high street trading environment remained difficult and had not been helped by the recent wet weather. Chairman Derek Netherton commented: “The business has also begun to benefit from the initiatives we are taking to simplify and centralise our operations, in preparation for accelerated expansion.” Greggs also noted the continued harmonisation of its ranges and new product launches as successes in the year to date, and is currently experimenting with a new ‘concept’ store in the south east.For the full story, see the next issue of British Baker – out 14 August.
Several local police agencies to conduct spring bus stop patrols (“31932 2011 Blue Bird 77 Maximum Passenger School Bus” by Bill McChesney, CC BY 2.0) Police in LaPorte and in Kosciusko County are among the 200 agencies ramping up enforcement this spring to protect students going to and from school. Over the next couple of months, officers will be positioned along bus stops and routes watching for stop-arm violations and unsafe driving behavior.The overtime patrols are funded by the National Highway Traffic Safety Administration through the state’s Stop Arm Violation Enforcement (SAVE) program, which was developed by the Indiana Criminal Justice Institute in 2019.High-visibility patrols will be conducted in the morning and afternoon along routes identified by local bus drivers and school transportation officials.While officers will be focusing on stop-arm violations, they will also be on the lookout for any unsafe driving behavior such as speeding and distracted driving.In Indiana, it’s against the law for motorists to pass a bus that’s stopped and has its red lights flashing and stop-arm extended. This applies to all roads, with one exception. Motorists who are on a highway that is divided by a barrier, such as a cable barrier, concrete wall or grassy median, are required to stop only if they are traveling in the same direction as the school bus.Click here for a list of school bus safety tips. Google+ IndianaLocalNews Facebook Google+ Previous articleDr. Wait: Homemade food sales are illegal, potentially hazardousNext articleReport: South Bend now tops for robberies in Indiana Jon ZimneyJon Zimney is the News and Programming Director for News/Talk 95.3 Michiana’s News Channel and host of the Fries With That podcast. Follow him on Twitter @jzimney. Twitter WhatsApp Pinterest Twitter By Jon Zimney – March 22, 2021 0 207 Pinterest WhatsApp Facebook
FSRH welcomes the new regulatory measures on sodium valproate medicines introduced by the MHRA. Evidence is clear that children born to women who take valproate during pregnancy are at a significant risk of birth defects and developmental disorders. Some of these drugs can affect how well some contraceptive methods work. However, women and girls who need these life-changing medications do not have to be left at risk for unplanned pregnancies. Our 2017 clinical guidance on drug interactions with hormonal contraception recommends that women and girls taking sodium valproate use highly-effective methods of contraception to avoid an unplanned pregnancy, both during treatment and for the recommended timeframe after discontinuation. Methods of contraception which are considered highly effective in this context include long-acting reversible contraceptives (LARCs) such as the copper IUD, levonorgestrel intrauterine system (LNG-IUS), the progestogen-only implant (IMP) and sterilisation. Women should seek advice from a specialist, who will carry out a pregnancy risk assessment and provide evidence-based advice on the most suitable method for them. In February this year, FSRH issued a clinical statement on contraception for women using known teratogenic drugs such as valproate, which is intended to support clinicians in providing high quality and consistent contraceptive advice. FSRH will keep working with its members to ensure they are aware of the MHRA decision and can advise women accordingly. Out of office hours: 07770 446 189 (17:00 – 08:30) Matthew Jolly, National Clinical Director for maternity and women’s health at NHS England, said: Dr Asha Kasliwal, president of the Faculty of Sexual and Reproductive Healthcare (FSRH), said: Clare Pelham, chief executive of Epilepsy Society, said: To protect public health, the Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate medicines (Epilim, Depakote and generic brands). Valproate must no longer be prescribed to women or girls of childbearing potential unless they are on the pregnancy prevention programme (PPP).Valproate is a treatment for epilepsy and bipolar disorder. Children born to women who take valproate during pregnancy are at significant risk of birth defects and persistent developmental disorders. If valproate is taken during pregnancy, up to 4 in 10 babies are at risk of developmental disorders, and approximately 1 in 10 are at risk of birth defects.Healthcare professionals who seek to prescribe valproate to their female patients must make sure they are enrolled in the PPP. This includes the completion of a signed risk acknowledgement form when their treatment is reviewed by a specialist, at least annually.All women and girls who are prescribed valproate should contact their GP and arrange to have their treatment reviewed. No woman or girl should stop taking valproate without medical advice.These regulatory changes will be further supported in the upcoming months by: Email [email protected] Our priority is always patients’ safety, so I welcome this decision to take strong actions to protect women and children. The focus will now be on explaining these changes to GPs and clinicians so they in turn can advise patients. Media enquiries FACSaware are absolutely delighted with the new measures as this will enable women to have an informed choice. We look forward to continuing our work with the MHRA to promote the importance of the Central Alerting System and the Yellow Card ADR reporting scheme. We are confident that fewer children will be born with this avoidable syndrome. By working with stakeholders we are definitely achieving our objectives. We welcome this action to reduce the risk of physical and developmental problems in children born to mothers who have taken valproate during pregnancy. Our clinical guideline on the management of epilepsy in pregnancy recommends that exposure to sodium valproate and other anti-epileptic drugs should be minimised by changing the medication prior to conception, as recommended by an epilepsy specialist after a careful evaluation of the potential risks and benefits. It’s important to note that stopping medication for long-term conditions completely or altering the dose can pose a serious risk to both mother and baby. Women are advised to seek advice from their GP and/or specialist team before conception or as soon as they are aware that they are pregnant. For women with epilepsy, the lowest effective dose of the most appropriate anti-epileptic drug should be prescribed and they should be looked after by a specialist team throughout pregnancy. These new regulatory measures are being supported across the NHS with other authorities also making changes – such as new GP system computer alerts – to make sure changes in prescribing behaviour take place promptly. NHS Digital has worked with GP systems suppliers to provide a search and audit function to identify women and girls on valproate as well as updating valproate prescribing alerts. A letter will be sent to all relevant healthcare professionals in the coming weeks outlining the new requirements and providing updated educational materials.In parallel, the National Institute for Health and Care Excellence (NICE) is amending its guidelines where valproate is mentioned, to reflect the new regulatory position. NICE has also begun work on a full update of its guideline on epilepsy. This will specifically focus on areas where valproate is currently regarded as the drug of choice and where this conflicts with the new position.Working together, across the health sector, these measures will help reduce the number of pregnancies exposed to valproate medicines to an absolute minimum and will make sure all women and girls of childbearing potential are aware of the risks.Since it was introduced in 1974, the information provided with valproate included a warning about the possible risk of birth defects. As with all medicines, the safety of valproate has been kept under constant review and as new data have become available, and the magnitude and the nature of the risks were better understood, warnings were updated – resulting in this most recent regulatory change.Dr June Raine, director of MHRA’s Vigilance and Risk Management of Medicines Division said: We welcome the new rules around prescribing valproate to women of childbearing age. It is essential the information about the changes reaches both the public and professionals, and that any women taking valproate are properly supported to come off the medication safely. Mind’s website has updated information about what these changes mean – visit mind.org.uk for details. Medicines and Healthcare products Regulatory Agency is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). MHRA is an executive agency of the Department of Health and Social Care. We welcome the revised measures which reflect the seriousness of the risks to the unborn children of women with epilepsy during pregnancy. Despite previous interventions, we know there are still far too many women who haven’t been made aware of the potential risks of taking sodium valproate in pregnancy. It is vitally important that healthcare professionals ensure that all women with epilepsy taking sodium valproate are reviewed in line with the new guidelines. We are working closely with the MHRA on the implementation of these new guidelines and will be looking to see if meaningful progress will be made in avoiding life-changing harm to children born to women with epilepsy. Patient safety is our highest priority. We are committed to making sure women and girls are aware of the very real risks of taking valproate during pregnancy. However, we also know it is vitally important women don’t stop taking valproate without first discussing it with their doctor. This regulatory position has been developed through close collaboration with professional bodies, health system organisations, and patient and campaign groups. I would like to particularly thank the families involved in the Valproate Stakeholder Network who have shared their experiences and expertise with us. Their support will help keep future generations of children safe. Carol Long, chief executive of Young Epilepsy, said: Professor Mark Baker, director of the Centre for Guidelines at NICE, said: Simon Wigglesworth, deputy chief executive of Epilepsy Action, said: Dr Angelika Wieck, Royal College of Psychiatrists Perinatal Faculty and Consultant Psychiatrist, Central Manchester University Hospital, said: Health Minister Lord O’Shaughnessy said: Stronger regulation over the use of valproate is welcome and will help ensure women get the advice and care they need. It is important pregnant women discuss their medication with their doctor and crucially do not stop taking it before seeking advice. The Royal Pharmaceutical Society fully supports these new measures to ensure women understand the risks of taking sodium valproate during pregnancy. They must get the right information from health professionals in order to make informed choices about their health and parenting options. Valproate is an effective medicine and women should never suddenly stop taking it without talking to a health professional. Pharmacists are ideally placed to give information and support when providing sodium valproate and are committed to reducing harm from medicines, enabling women to make the choices that are right for them. EndsNotes to Editor Emma Friedmann, campaign director of #FACSaware, said: During office hours: 020 3080 7651 (08:30 – 17:00) Carol Lapidge & Susan Cole, OACS (Organisation for Anti-Convulsant Syndrome) Charity, said: The ABN welcomes these important new measures. It is vital that all neurologists are aware of the changes to the licensing of valproate. We will disseminate information around the new measures to our membership through our publications, website and bulletins. We will also include links to a variety of resources and organisations, including support groups, and remind our membership about the Epilepsy and Pregnancy Register. It cannot be stressed enough that no women should stop taking this medication without medical advice. Young Epilepsy welcomes the MHRA’s strengthened regulatory position for women of childbearing potential, who are diagnosed with epilepsy and prescribed sodium valproate. In ensuring such women receiving a Pregnancy Prevention Programme (PPP), they will have greater knowledge in realising the potential risks taking the drug has to the unborn child. It is vital that women who may be planning to have a family receive the right advice at the right time; to prevent their unborn babies being put at risk. Sodium valproate can provide life-changing support for many young people with epilepsy. It is the third most-prescribed anti-epilepsy medication, however, the percentage of women who do not know the risks of taking the drug during pregnancy is far too high. That information must be made clearer, and medical professionals must be given more support to understand and be proactive in flagging the risks. Women must feel more empowered to discuss the issue with their epilepsy specialist, so that they can make a more informed decision about their future. INFACT welcome the changes made to the licence for Valproate and are pleased and very proud to have instigated and helped drive this forward following 6 years campaigning at Parliament for those changes. It is important that all women prescribed Valproate are made aware of the risks when taken in pregnancy in order to safeguard their future children from disabilities, and INFACT applaud the decision made by the MHRA to ensure that risk is minimal. Karen Keely, chairperson of OACS Ireland, said: OACS Ireland welcomes the new regulatory measures by MHRA Epilim (Valproate) UK Toolkit. Women and men were prescribed this drug as far back as 1973 in the UK with many children harmed worldwide. OACS Ireland welcomes the MHRA efforts to make changes to the way valproate is prescribed to prevent further harm. They brought their concerns to the attention of the EMA and therefore to all EU Nations including Ireland. By ensuring that the Epilim (Valproate) toolkit is securely put in place alongside Pregnancy Prevention Program (PPP) we hope to ensure this is followed by all. We have been working with MHRA for many years now and hope to assist them with their work as much as possible by ensuring the valproate toolkit is followed. We hope that the new guidance will be followed by all. As part of the stakeholder’s network group run by the MHRA which has resulted in inclusive and constructive engagement with groups across the UK and Ireland’s health, science and digital sectors alongside patient groups. Although this process has been a difficult it has been hugely constructive. Without the UK MHRA contributions to the EMA many mothers would not have known the risks of this drug. Stephen Buckley, head of Information at Mind, the mental health charity, said: On behalf of the Association of British Neurologists (ABN) by Professor Mary M Reilly, President, and Professor Sanjay Sisodiya, Chair of the ABN Epilepsy Advisory Group, said: Professor Helen Stokes-Lampard, chair of the Royal College of GPs, said: This is a good example of how IT systems can support important issues affecting public health. We have been working closely with the MHRA and GP system suppliers to ensure clinicians in primary care are informed of the risks of prescribing sodium valproate to certain patients. All GP systems have alerts applied and we are continuing to work with some of the suppliers to ensure these high visibility alerts are consistent across primary care. These alerts ensure that GPs are prompted at the time of prescribing. We have also worked with community pharmacy dispensing system suppliers to ensure that the alerts are also shown when prescriptions are dispensed. This includes changes to prescription labels so that patients are made aware of the risks and the need for reliable contraceptive precautions. We will continue to work with supplier partners in evolving system to maximise safety and minimise burden on clinicians and patients as guidance evolves. Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk Professor Ash Soni, president of the Royal Pharmaceutical Society, said: Janet Williams & Emma Murphy, INFACT, said: ensure the patient understands the risks to the unborn child of using valproate during pregnancy and provide patient guide ensure the patient understands the need to comply with contraception throughout treatment and undergo pregnancy testing when required e.g. if there is any reason to suggest lack of compliance or effectiveness of contraception complete and sign the acknowledgement of risk form (at every annual visit), give a copy to the patient and send one to the GP refer for contraception services as needed News centreMHRA10 South ColonnadeLondonE14 4PU Valproate can cause harm to unborn children so banning its use in women with mental disorder who are pregnant, or could get pregnant, is welcome. It cannot be stressed enough that no women should stop taking this medication without medical advice. Managing mental health is particularly important for women who are pregnant or plan to get pregnant. It is essential that all women are better informed about the risks of Valproate to unborn children and that any use of this drug in pregnancy will be monitored. RCPsych will work with the MHRA and other Government bodies, the Royal Colleges of General Practitioners, Physicians, Obstetricians and Gynaecologists and the Royal Pharmaceutical Society to implement changes in clinical practice and support affected women. OACS Charity welcomes the prevention measures agreed by MHRA who have consulted with us alongside other campaign groups over the past two years. Since January 2016 OACS Charity has attended every meeting of the Valproate Stakeholder’s Network and we are appreciative that the MHRA has developed this progressive forum for discussion. Next year OACS will be celebrating 20 years supporting and representing families affected by fetal valproate syndrome and we are pleased that the MHRA has developed this progressive forum for discussion. Their work with stakeholders has resulted in inclusive and constructive engagement with groups across the UK health, science and digital sectors alongside patient groups. This has been a difficult but hugely constructive journey. We believe that this process, led by June Raine, will pave the way for other groups who have been adversely affected by medicines in the past. If you have been affected by sodium valproate please see our website oacscharity.org. These are very welcome measures that will enable midwives to advise and support women about this issue. We are actively putting this information out to our members including on social media and via the RCM’s website so that our members are informed about this important update. We have also updated our online learning package on epilepsy and pregnancy to reflect these changes. MHRA actively encourages patients and healthcare professionals to report suspected side effects through the Yellow Card Scheme As part of the pregnancy prevention programme (PPP) the prescriber must: The most important change today is that every woman and girl of childbearing age who has been prescribed sodium valproate will be able to see her doctor every year to discuss the risks of this drug to an unborn baby. She will leave the discussion with an important written reminder of the risks if sodium valproate is taken during pregnancy. This means that she will be able to make informed choices about whether to plan a pregnancy and her future medical treatment. It has taken many years to achieve these simple, straightforward and inexpensive healthcare improvements that will prevent babies being born with avoidable disabilities. All credit to the brave women who have campaigned for decades. And to Jeremy Hunt for acting on that campaign and insisting the NHS must now learn from its failure to listen and act sooner in response to the concerns raised over many years and during many governments. At Epilepsy Society we shall be diligently monitoring the implementation on the ground in order to confirm that it is robust and effective. Rachel Scanlan, professional advisor at the Royal College of Midwives, said: Mr Edward Morris, vice president for clinical quality at the Royal College of Obstetricians and Gynaecologists, said: Nic Fox, director of Primary and Social Care Technology at NHS Digital said: GPs are acutely aware of the risks associated with prescribing sodium valproate to women of childbearing age and we welcome this change in legislation as a logical way forward to help ensure our patients’ safety. However, any patients currently taking sodium valproate should not stop doing so without seeking expert medical advice. As a general rule, it is important that patients read and take heed of warnings on the packets of any medication they are taking – and that any woman on long-term medication speaks to their GP if they are planning to have a baby. smaller pack sizes to encourage monthly prescribing a pictogram/warning image on valproate labelling NICE welcomes restricting the use of valproate in women of childbearing potential. It’s important that everyone affected by these changes is made aware of them as soon as possible. We have therefore taken immediate steps to amend our guidelines on the diagnosis and management of epilepsies, the assessment and management of bipolar disorder, depression in adults, and antenatal and postnatal mental health to reflect this important change to the drug’s licence. We will use our communications networks to highlight the changes, both to healthcare professionals and to patients, to help ensure that the number of children exposed to valproate through their mother during pregnancy is kept to an absolute minimum.
Sea temperature patterns predict extreme temperatures Related Earlier warnings for heat waves This increase could lead to more respiratory illnesses, with especially dangerous consequences for children, seniors, and people suffering from asthma.“Short-term exposure to ozone has been linked to adverse health effects,” said Loretta J. Mickley, a co-author of the study. “High levels of ozone can exacerbate chronic lung disease and even increase mortality rates.”While temperature has long been known as an important driver of ozone episodes, it’s been unclear how increasing global temperatures will impact the severity and frequency of surface level ozone.To address this question, Shen and Mickley — with co-author Eric Gilleland of the National Center for Atmospheric Research (NCAR) — developed a model that used observed relationships between temperature and ozone to predict future ozone episodes.Previous research had not relied so heavily on existing observations, making projections uncertain. Shen and co-authors analyzed ozone-temperature relationships at measurement sites across the United States, and found them surprisingly complex.“Typically, when the temperature increases, so does surface ozone,” said Mickley.“Ozone production accelerates at high temperatures, and emissions of the natural components of ozone increase. High temperatures are also accompanied by weak winds, causing the atmosphere to stagnate. So the air just cooks and ozone levels can build up.”However, at extremely high temperatures — beginning in the mid-90s Fahrenheit — ozone levels at many sites stop rising with temperature. The phenomenon, previously observed only in California, is known as ozone suppression.California, the Southwest, and the Northeast would be the most affected, each possibly experiencing up to nine additional days of dangerous ozone levels, with much of the rest of the country experiencing an average increase of 2.3 days.In order to better predict future ozone episodes, the team set out to find evidence of ozone suppression outside of California and test whether or not the phenomenon was actually caused by chemistry.They found that 20 percent of measurement sites in the United States show ozone suppression at extremely high temperatures. Their results called into question the prevailing view that the phenomenon is caused by complex atmospheric chemistry.“Rather than being caused by chemistry, we found that this dropping off of ozone levels is actually caused by meteorology,” said Shen. “Typically, ozone is tightly correlated with temperature, which in turn is tightly correlated with other meteorological variables such as solar radiation, circulation, and atmospheric stagnation. But at extreme temperatures, these relationships break down.”“This research gives us a much better understanding of how ozone and temperature are related and how that will affect future air quality,” said Mickley. “These results show that we need ambitious emissions controls to offset the potential of more than a week of additional days with unhealthy ozone levels.”This research was supported by the NASA Air Quality Applied Sciences Team and the National Institute of Environmental Health Sciences. If emission rates continue unchecked, regions of the United States could experience between three and nine additional days per year of unhealthy ozone levels by 2050, according to a new study from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) published in Geophysical Research Letters.“In the coming decades, global climate change will likely cause more heat waves during the summer, which in turn could cause a 70 to 100 percent increase in ozone episodes, depending on the region,” said first author Lu Shen, a Ph.D. candidate at SEAS and the Graduate School of Arts and Sciences.California, the Southwest, and the Northeast would be the most affected, each possibly experiencing up to nine additional days of dangerous ozone levels, with much of the rest of the country experiencing an average increase of 2.3 days.
By Dialogo February 17, 2011 Brazilian Defense Minister Nelson Jobim said on 15 February his ministry will cut up to $2.4 billion from its budget this year, without affecting a pending multibillion dollar fighter aircraft contract. Jobim said the Defense Ministry has a budget of about 8.9 billion dollars but will cut just over 26 percent of its spending. He met with President Dilma Rousseff for over three hours to discuss the budget. “I will meet with representatives of the different branches of the armed forces and distribute the cuts among them,” Jobim told reporters, but emphasized the cuts would have no impact on Brazil’s stalled purchase of 36 fighter planes. France, Sweden and the United States are vying for the contract, which has an initial value estimated at $4 to $10 billion, with the possibility of many more aircraft in the future. “There are no budget expenditures this year for the fighter,” Jobim said, noting that it would take “at least a year” to choose the best bidder and begin complex negotiations on technical matters and the terms of the deal. He said he expected a decision this year. The competition has dragged on for years, with Rousseff inheriting it from her predecessor Luiz Inacio Lula da Silva. Jobim has said the only fighters under consideration were the French-made Rafale, the Swedish Gripen NG and the US F-18 Super Hornet. Brazil wants the deal to include not just the aircraft but also technology transfers. Lula had said he favored the Rafale, but in the end opted to leave the decision to his successor.
January 1, 2006 Regular News Forty-four years ago, Francisco “Frank” Angones landed in South Florida from Cuba, alone, without even his parents, as part of a program called Peter Pan that brought Cuban children to this country.Now more than four eventful decades later — which have seen Angones both achieve greatly and give back to his profession and community — he has been elected 2006-2007 president-elect of The Florida Bar, following the close of election filing December 15.Angones was the only candidate to submit enough signatures to qualify. Around 690 signatures are required and Angones submitted more than 3,000. He will be sworn in as president-elect at the June Annual Meeting, when President-elect Hank Coxe is sworn in as president. Then in June 2007, Angones will become the first Cuban-born president of The Florida Bar.“I feel both extremely honored for the support that I got from other lawyers not only in South Florida but throughout the state and I’m truly humbled,” Angones said. “I came to the United States without my parents in 1961 in a program called Peter Pan [his parents did join him four months later], and some 40 years later, I’m going to be president of The Florida Bar. Only in America.”Angones said he was inspired to seek the Bar’s top spot by former President C. Clyde Atkins, who went on to become chief judge of the federal court’s Southern District of Florida. He recalled how Atkins wound up overseeing the desegregation of South Florida schools, and arranged to have his grandchildren moved from parochial to public schools.“He believed in leading by example,” he said. “He was kind, gentle, yet firm in principle.”Those are traits Angones hopes to bring to what he sees as some tough challenges for the Bar.“I think more and more it has become important for The Florida Bar to interact with the legislature and the executive branch,” he said. “We are part of the judiciary. We need to have a fair and impartial judiciary and to do so we need to interact more than we have in the past with the legislature and the executive branch.“We all want to have better government for Florida.”Angones also said he wants to continue the Bar’s diversity efforts begun by former President Miles McGrane and continued by former President Kelly Overstreet Johnson, President Alan Bookman, and President-elect Hank Coxe.“We have been doing a great job in the past two to three years of diversifying the Bar, not just paying lip service, but going out and seeking participation of all groups,” he said, adding that applies to both geographic as well as ethnic issues.Angones also said he liked Bookman’s program last summer that brought Bar leaders and the Bar’s sections together. He said he’d like to continue that and expand it to voluntary bars, including special interest bars, such as for trial and criminal lawyers.Angones practices civil trial, personal injury, commercial torts, and insurance litigation in Miami at the firm he co-founded, Angones, McClure & Garcia, P.A. He received his bachelor’s degree magna cum laude from the University of Miami in 1972 and his law degree from UM in 1976.He is a past president of both the Dade County Bar Association and the Cuban American Bar Association, is a member of the House of Delegates of the ABA, and has served on the Federal Judicial Nominating Commission for the Southern District, among many other bar-related activities.He has also been active in a variety of civic organizations including serving on the board of the Miami-Dade Community Relations Board, on the Executive Committee of the Miami Coalition for a Safe and Drug Free Community, and chair of Victoria Hospital’s Board of Directors.He is married to Georgina and their son, Frank, recently graduated from Columbia University.While that might seem like an impressive resume for someone who landed on these shores in 1961, Angones is thankful and sees it as an essentially American story.“This country opened its arms to me and many other Cuban Americans and many other immigrants,” he said. “This is really the place where you have opportunity for upward mobility and if you’re not afraid to work hard and sacrifice, the United States of America is the place to be.” Angones named president-elect Angones named president-elect
ShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr by: Brandon KuehlIn a new white paper, “U.S. Participates in the Global Fight Against Card Fraud,” TMG Product Manager Brandon Bogler and I take a look at what tokenization means for card-issuing financial institutions.Below is an excerpt from the paper breaking down the first steps of implementing tokenization to supplement EMV in fraud prevention:As with EMV, the decision to enable a credit or debit card portfolio for tokenization resides with the issuer. It is not a requirement, nor have the card brands issued any mandates. However, we anticipate Visa, MasterCard and potentially others to take a similar stance on tokenization as they have with EMV, namely with the establishment of liability shifts or similar incentives.So, what does it take to enroll a portfolio for tokenization? Card issuers will be happy to learn there are far fewer decisions to make and steps to take than with EMV implementation. continue reading »
The House on Thursday passed a fiscal 2018 spending package (H.R. 3354), which contains some NAFCU-sought regulatory relief provisions and NAFCU-sought funding for the NCUA Community Development Revolving Loan Fund.“NAFCU appreciates lawmakers including much-needed regulatory relief for the credit union industry in this 2018 spending package,” said NAFCU President and CEO Dan Berger. “We will continue to push to roll back unnecessary regulations so credit unions can better serve their communities and 110 million members.”In a victory for credit unions, the spending package that passed Thursday also includes a NAFCU-supported measure that would remove the CFPB’s authority to regulate for unfair, deceptive and abusive acts or practices (UDAAP) and would wrap the CFPB into the congressional appropriations process. The bill also repeals the bureau’s ability to write arbitration rules and require the collection and reporting of small-business data. It would also provide qualified mortgage relief to certain mortgage loans held in portfolio. These provisions were also passed by the House earlier this year as part of the NAFCU-backed Financial CHOICE Act. continue reading » 9SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr
ShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr In a span of a few years between the mid-70s and early-80s, our family went from upper-middle class to simply put, poor. Growing up in northwest Arkansas, at the edge of the Ozarks and Boston Mountains, we came up as one of the few old-money families in the area – and, as a kid, it was great!In my pre-teen years, for a number of reasons, it all went away. My brother, sister and I all had to get jobs by the time I was 12 to help pay bills, buy our own coats and those kinds of things. For me, I processed the situation into a motivation to work hard, earn some money and get myself into college.Going to and graduating from a university, for me, was one of the best/worst decisions I’ve made. It opened doors to internships and eventually one of those internships led to my first job in journalism. The downside of it all was the enormous financial stress it placed on my head for years in trying to land financial aid or get a couple of extra restaurant jobs to cover the costs of that education. At the time, I had the strange opportunity to talk to the university president one-on-one about it. I told him, “The way the system is set up makes future me regret what I’m doing here.” His response, in part, was, “It’s about the experience, Mr. Ogden.” continue reading »
Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York HOPE RUNS HEREProceeds from this 5-mile run benefit the LI2Day Breast Cancer Walk, Inc., a 501(c)3 dedicated to raising funds to support local Long Island breast cancer coalitions and Islip Breast Cancer Coalition. Islip Town Hall, 655 Main St., Islip, runsignup.com $25. 8 a.m. Oct. 6.POSITIVELY PINKA breast health awareness event. Westfeild South Shore Mall, 1701 Sunrise Hwy., Bay Shore, goodsamaritan.chsli.org 10:30 a.m. Oct. 10.STRONGER THAN CANCER 5KThe annual event benefits SJJCC’s Nancy Marx Cancer Wellness Center, which provides much-needed programming including exercise classes, discussion groups, counseling services, and more. Sid Jacobson Jewish Community Center, 300 Forest Dr., East Hills, sjjcc.org/5k $25. 9:30 a.m. Oct. 13.A WORLD OF PINK GALA AND FASHION SHOWProceeds benefit World of Pink Foundation which has provided to date thousands of free prostheses and pocketed bras for women who don’t have insurance and couldn’t otherwise afford breast aftercare following surgery. Watermill Caterers at 711 Smithtown Bypass, Smithtown, aworldofpink.com $125. 6:30 p.m. Oct. 16.LADIES’ NIGHT OUTThis annual fundraiser helps the Manhasset Women’s Coalition Against Breast Cancer continue its mission f funding innovative research, increasing awareness through education and providing support services. Leonard’s Palazzo, 555 Northern Blvd., Great Neck, manhassetbreastcancer.org $115. 6:30 p.m. Oct. 16.STRIDES AGAINST BREAST CANCER WALKSurvivors and supporters of Making Strides of Long Island step out in Long Island’s largest annual walk to raise awareness and money for the American Cancer Society. Co-sponsored by Long Island Press. Jones Beach State Park Field 5, Ocean Parkway, Wantagh, acsevents.org 7 a.m. Oct. 20.COMMUNITY BAG PROGRAMWith every purchase of the $2.50 reusable Community Bag, Stop and Shop donates to a local nonprofit, such as the West Islip Breast Cancer Coalition when a purchase is made at the West Islip location. Stop and Shop, multiple locations, stopandshop.bags4mycause.com Ongoing.BREAST CANCER SEMINARS HIGHLIGHT PREVENTIONNorthwell Health will host two breast cancer-related seminars in the Huntington area in October. The first event is for women to learn more about their risk of breast cancer as well as ways to prevent, screen and treat this disease. The event will be held at 5:30 p.m. on Oct. 23 at at the Dolan Family Health Center in Greenlawn. At the second event, women who have breast cancer and are thinking about breast reconstruction surgery can learn about available options, including 3D microsurgery, robotic mastectomy and lymphatic reconstruction from a panel of experts and breast reconstruction patients. The event will take place at 10 a.m. on Oct. 26 at the Huntington Country Club.